NuOrtho Surgical Names Darik Volpa to Board of Directors

Share Article

Jeffrey Morrill, CEO of NuOrtho Surgical, Inc. of Fall River, Massachusetts, is pleased to announce that Darik Volpa, CEO of Understand.com, has joined its Board of Directors. Mr. Volpa has led the privately held company to seven straight years of record sales growth.

Jeffrey Morrill, CEO of NuOrtho Surgical, Inc. of Fall River, Massachusetts, is pleased to announce that Darik Volpa, CEO of Understand.com, has joined its Board of Directors.

“Darik Volpa is a great addition to our Board of Directors. As the founder and CEO of Understand.com, a global provider of medical content that helps healthcare professionals and companies better communicate diseases, conditions, and procedures to patients using 3D animation, Darik is well suited for NuOrtho,” stated Morrill.

Mr. Volpa gained much of his experience at Stryker Corporation, a $6 billion medical device company, where he served in various sales and marketing roles for nine years. While at Stryker, Mr. Volpa managed more than $50 million in products and commercially launched the first synthetically engineered bone morphogenetic protein (BMP).

Mr. Volpa was named the 2007 Innovator of the Year by The Business Report of Northern Nevada. In 2006, Mr. Volpa was awarded "Best of Show" at the Silver & Gold Venture Capital Conference representing Understand.com. In 2009, the company was a finalist for “Best Places to Work” in Northern Nevada by the Economic Development Authority of Western Nevada. Mr. Volpa was the recipient of the Reno Gazette Journal “20 Under 40” award, and he was named a “20/20 Business Visionary” by Nevada Business Magazine.

Understand.com has educated more than 5,000,000 patients and has thousands of clients licensing content globally. Mr. Volpa has led the privately held company to seven straight years of record sales growth.

NuOrtho Surgical is focused on the manufacture of surgical instruments that enable Tissue Preservation™ in the orthopedic arena to improve patient outcomes. NuOrtho has three primary product platforms for preserving healthy tissue to sustain long-term mobility. These platforms include Soft Tissue Treatment, Agent Delivery and Bone Fusion. NuOrtho’s first product launch will be Ceruleau™, a revolutionary product for soft tissue treatment in knee procedures for cartilage. The company has nine patents providing significant business opportunities. For further information visit http://www.nuortho.com.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Jeffrey Morrill
Visit website